WO2022130848A1 - 外用医薬組成物 - Google Patents
外用医薬組成物 Download PDFInfo
- Publication number
- WO2022130848A1 WO2022130848A1 PCT/JP2021/041550 JP2021041550W WO2022130848A1 WO 2022130848 A1 WO2022130848 A1 WO 2022130848A1 JP 2021041550 W JP2021041550 W JP 2021041550W WO 2022130848 A1 WO2022130848 A1 WO 2022130848A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- external pharmaceutical
- weight
- present
- monoterpene
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 69
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 53
- 229930003658 monoterpene Natural products 0.000 claims abstract description 37
- 150000002773 monoterpene derivatives Chemical class 0.000 claims abstract description 37
- 235000002577 monoterpenes Nutrition 0.000 claims abstract description 37
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 27
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 13
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 14
- 229960002373 loxoprofen Drugs 0.000 claims description 11
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 claims description 11
- 229940041616 menthol Drugs 0.000 claims description 11
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 claims description 8
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 8
- 229960000192 felbinac Drugs 0.000 claims description 8
- 229960001259 diclofenac Drugs 0.000 claims description 7
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 11
- 238000009472 formulation Methods 0.000 abstract description 8
- 230000035807 sensation Effects 0.000 abstract 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- -1 fervinac Chemical compound 0.000 description 15
- 229960004063 propylene glycol Drugs 0.000 description 15
- 235000013772 propylene glycol Nutrition 0.000 description 15
- 230000035597 cooling sensation Effects 0.000 description 13
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 3
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 3
- 239000005792 Geraniol Substances 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229960001193 diclofenac sodium Drugs 0.000 description 3
- 229940113087 geraniol Drugs 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 3
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 229960005293 etodolac Drugs 0.000 description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- SGAWOGXMMPSZPB-UHFFFAOYSA-N safranal Chemical compound CC1=C(C=O)C(C)(C)CC=C1 SGAWOGXMMPSZPB-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- DJEIHHYCDCTAAH-UHFFFAOYSA-N Mofezolac (TN) Chemical compound C1=CC(OC)=CC=C1C1=NOC(CC(O)=O)=C1C1=CC=C(OC)C=C1 DJEIHHYCDCTAAH-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 239000004146 Propane-1,2-diol Substances 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 229960000429 mofezolac Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000017509 safranal Nutrition 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to an external pharmaceutical composition containing a non-steroidal anti-inflammatory drug and a monoterpene and having an improved cooling sensation.
- Non-steroidal anti-inflammatory drugs typified by loxoprofen sodium, diclofenac sodium, felbinac, etc. are widely used as active ingredients in external pharmaceutical compositions. Further, since monoterpenes such as menthol exhibit a cool feeling, they are used for the purpose of improving the usability of the external pharmaceutical composition.
- Patent Document 1 describes that an external pharmaceutical composition containing loxoprofen and / or a salt thereof, menthol, ethanol, and water can suppress cloudiness.
- Patent Document 2 the external pharmaceutical composition containing diclofenac and / or a salt thereof, tocopherol and / or a derivative thereof, menthol, and water suppresses cloudiness and formation of precipitates, and has excellent appearance properties. It is stated that it may be provided.
- Patent Document 3 the oil-in-water emulsified external preparation having felbinac, l-menthol, polyhydric alcohol, and triglyceride and having a pH of 6.5 to 8.0 reduces the content of felbinac. It is stated that it can be suppressed.
- An object of the present invention is to provide a technique for improving the cool feeling exhibited by an external pharmaceutical composition containing a non-steroidal anti-inflammatory drug and a monoterpene.
- the present inventor has made diligent studies to solve the above problems, and found that the external pharmaceutical composition containing a non-steroidal anti-inflammatory drug and monoterpene contains propylene glycol in a content of more than 10% by weight. , Found that it can improve the feeling of coolness.
- the present invention has been completed by further studies based on such findings.
- Item 1 Contains (A) non-steroidal anti-inflammatory drugs, (B) monoterpenes, and (C) propylene glycol.
- a pharmaceutical composition for external use wherein the content of the component (C) is more than 10% by weight.
- Item 2. Item 2. The external pharmaceutical composition according to Item 1, wherein the component (A) is at least one selected from the group consisting of loxoprofen, diclofenac, felbinac, and salts thereof.
- Item 3. Item 2. The external pharmaceutical composition according to Item 1 or 2, wherein the component (B) is menthol and the content of menthol is 2 to 5% by weight.
- a method for improving the coolness of an external pharmaceutical composition containing a non-steroidal anti-inflammatory drug and a monoterpene A method for improving a cool feeling, in which (A) a non-steroidal anti-inflammatory drug, (B) a monoterpene, and (C) propylene glycol in an amount of more than 10% by weight are blended in an external pharmaceutical composition.
- the present invention it is possible to improve the cool feeling exhibited by an external pharmaceutical composition containing a non-steroidal anti-inflammatory drug and a monoterpene, and to provide an excellent feeling of use. Further, according to the present invention, even if the monoterpene is set to a low content (for example, 5% by weight or less) at which skin irritation is unlikely to appear, an excellent cooling sensation can be exhibited, and thus a preparation having low skin irritation. It can also correspond to the prescription.
- a low content for example, 5% by weight or less
- the external pharmaceutical composition of the present invention contains (A) a non-steroidal anti-inflammatory drug, (B) a monoterpene, and (C) propylene glycol, and the content of the component (C) is 10% by weight. It is characterized by being super.
- the external pharmaceutical composition of the present invention will be described in detail.
- Non-steroidal anti-inflammatory drug contains a non-steroidal anti-inflammatory drug (sometimes referred to as component (A)).
- Non-steroidal anti-inflammatory drug is a general term for anti-inflammatory drugs other than glucocorticoids.
- non-steroidal anti-inflammatory drug used in the present invention is not particularly limited, and for example, loxoprofen, diclofenac, fervinac, salicylic acid, acetylsalicylic acid, aspirin, salsalate, salicylamide, etodolac, ibuprofen, ketoprofen, naproxen, etc.
- non-steroidal anti-inflammatory drug may be in the form of a salt if it can be in the form of a salt.
- examples of the non-steroidal anti-inflammatory drug in the form of a salt include a salt of loxoprofen, a salt of diclofenac and the like.
- the salt of loxoprofen examples include alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as calcium salt. Among these, an alkali metal salt is preferable, and a sodium salt is more preferable. Further, the salt of loxoprofen may be a hydrate.
- diclofenac salt examples include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt; salts with ammonia; dimethylamine, diethylamine, trimethylamine, triethylamine and the like. Examples thereof include salts with primary, secondary or tertiary alkylamines. Among these, an alkali metal salt is preferable, and a sodium salt is more preferable.
- non-steroidal anti-inflammatory drugs may be used alone or in combination of two or more.
- non-steroidal anti-inflammatory drugs loxoprofen, diclofenac, felbinac, and salts thereof are preferable.
- the content of the component (A) in the external pharmaceutical composition of the present invention may be appropriately set according to the type of the component (A) to be used, the medicinal effect to be provided, and the like, and is, for example, 0.1 to 15% by weight. It is preferably 0.5 to 10% by weight, more preferably 0.5 to 5% by weight.
- the external pharmaceutical composition of the present invention contains a monoterpene (sometimes referred to as a component (B)).
- the monoterpene is a known component having a structure in which two isoprene units are contained in a molecule and having a cooling action and the like.
- the type of monoterpene used in the present invention is not particularly limited as long as it is pharmaceutically acceptable, but is, for example, an alcohol-based monoterpene such as menthol, timole, geraniol, linalol, borneol, cineole, and terpeneol.
- Aldehyde-based monoterpenes such as citral, citroneral, perylaldehyde, and safranal; ketone-based monoterpenes such as camphor, menthol, carbomenton, and yonon can be mentioned.
- These monoterpenes may be d-form, l-form, or dl-form when optical isomers are present. These monoterpenes may be used alone or in combination of two or more.
- an essential oil containing a monoterpene may be used as the monoterpene.
- the essential oil containing monoterpene can be appropriately selected from known ones and used.
- the essential oil containing menthol includes peppermint oil, peppermint oil, sparemint oil and the like.
- the description about the content and ratio of monoterpenes in this specification is a value converted into the amount of monoterpenes contained in the essential oil when the essential oil containing monoterpenes is used.
- menthol geraniol, d-borneol, dl-camphor, and more preferably l-menthol are preferable.
- the content of the component (B) in the external pharmaceutical composition of the present invention may be appropriately set according to the type of the component (B), the feeling of coolness to be provided, etc., but for example, the total amount of the component (B) may be used. 0.01 to 10% by weight, preferably 0.1 to 8% by weight, more preferably 1 to 6% by weight, still more preferably 2 to 5% by weight, and particularly preferably 2 to 4% by weight.
- the cooling sensation is improved by containing propylene glycol, which will be described later, in a content of more than 10% by weight, together with the non-steroidal anti-inflammatory drug and monoterpene. Even if the content of the component is about 5% by weight or less, which is less likely to cause skin irritation, an excellent cooling sensation can be provided.
- the ratio of the component (B) to the component (A) is determined according to the content of each of these components.
- the components are 0.001 to 100 parts by weight, preferably 0.01 to 10 parts by weight, and more preferably 0.1 to 10 parts by weight.
- the external pharmaceutical composition of the present invention contains propylene glycol (sometimes referred to as component (C)) in an amount of more than 10% by weight in addition to the above-mentioned components.
- propylene glycol is a divalent lower alcohol also called propane-1,2-diol.
- the content of the component (C) in the external pharmaceutical composition of the present invention may be more than 10% by weight, and specific examples thereof include more than 10% by weight and 50% by weight or less. From the viewpoint of further improving the cooling sensation, the content of the component (C) in the external pharmaceutical composition of the present invention is preferably 11 to 40% by weight, more preferably 13 to 30% by weight, still more preferably 15 to 30% by weight, particularly preferably 15 to 20% by weight.
- the ratio of the component (C) to the component (A) is determined according to the content of each of these components.
- the component are 0.1 to 100 parts by weight, preferably 0.5 to 100 parts by weight, and more preferably 1 to 40 parts by weight.
- the external pharmaceutical composition of the present invention may further contain a monohydric lower alcohol.
- the monohydric lower alcohol refers to a monohydric alcohol having 1 to 5 carbon atoms.
- the type of monohydric lower alcohol is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include ethanol, n-propanol, and isopropanol. These monohydric lower alcohols may be used alone or in combination of two or more.
- ethanol is preferable.
- the content thereof is not particularly limited, but is, for example, 0.1 to 88% by weight, preferably 25 to 80% by weight, more preferably 50. -80% by weight can be mentioned.
- the external pharmaceutical composition of the present invention may contain other commonly used additives, if necessary.
- additives include water, surfactants, vegetable oils, animal oils, mineral oils, fatty acid alkyl esters, fatty acids, higher alcohols, pH adjusters, buffers, solubilizers, preservatives, preservatives and oxidations.
- examples include inhibitor, stabilizer, fragrance, colorant and the like.
- the external pharmaceutical composition of the present invention may contain a pharmacological component in addition to the above-mentioned components.
- pharmacological components include antihistamines, local anesthetics, moisturizers, bactericides, antibacterial agents, antipruritic agents, skin protectants, blood circulation promoting components, vitamins and the like. These pharmacological components may be used alone or in combination of two or more.
- the concentration thereof may be appropriately set according to the type of the pharmacological component used, the expected effect, and the like.
- the pharmaceutical composition for external use of the present invention is not particularly limited in its formulation form as long as it is a dosage form that can be applied transdermally, and may be liquid or semi-solid (gel, ointment, paste). It is good, but preferably liquid.
- composition form of the external pharmaceutical composition of the present invention examples include liquids, creams, lotions, gels, emulsions, aerosols and the like.
- a liquid agent is preferable.
- Preparation of these formulations can be carried out by formulating them with additives according to the formulation form according to the known method described in the 17th revised Japanese Pharmacopoeia General Regulations for Formulations and the like.
- the present invention further comprises a method for improving the cooling feeling of an external pharmaceutical composition containing a non-steroidal anti-inflammatory drug and monoterpene, wherein the external pharmaceutical composition is (A) non-steroidal.
- a method for improving a cooling sensation which comprises blending an anti-inflammatory drug, (B) monoterpene, and (C) propylene glycol in an amount of more than 10% by weight.
- the types of the components (A) and (B), the blending amounts of the components (A) to (C), the types and contents of other components to be blended, and the external pharmaceutical composition are the same as in the case of "1. External pharmaceutical composition".
- Test Example A pharmaceutical composition (liquid preparation) for external use having the composition shown in Tables 1 to 3 was prepared.
- the cool feeling exhibited by each of the obtained external pharmaceutical compositions was evaluated. Specifically, about 2 g of each external pharmaceutical composition was applied to the inner arm of 10 subjects, and 30 minutes after the application, the cool feeling in the applied portion was evaluated on a 20-point scale.
- the evaluation of the cool feeling was 1 point for "no cool feeling at all", 15 points for "cool feeling felt when the external pharmaceutical composition of Reference Examples 1-1, 2-1 or 3-1 was used”. With “extremely good and high cooling sensation" as 20 points, the scores were graded on a scale of 1 to 20 according to the degree of cooling sensation, and the average score of the scores of 10 subjects was calculated.
- the average score when the external pharmaceutical composition of Comparative Examples 1-1, 2-1 or 3-1 is used is set to 100, and the ratio of the average score when each external pharmaceutical composition is used is set.
- the value calculated and rounded off to the first decimal place was used as the coolness score.
- a pharmaceutical composition for external use having the composition shown in Table 4 of Prescription Example 4 was prepared by the same method as in Test Example 1, and the cool feeling was evaluated by the same method as in Test Example 1.
- any of the external pharmaceutical compositions of Formulation Examples 1 to 12 a dramatic improvement in the cooling sensation was observed as compared with the external pharmaceutical compositions in which propylene glycol was changed to no compound in Formulation Examples 1 to 12.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
項1. (A)非ステロイド性抗炎症薬、(B)モノテルペン、及び(C)プロピレングリコールを含み、
前記(C)成分の含有量が10重量%超である、外用医薬組成物。
項2. 前記(A)成分が、ロキソプロフェン、ジクロフェナク、フェルビナク、及びこれらの塩よりなる群から選択される少なくとも1種である、項1に記載の外用医薬組成物。
項3. 前記(B)成分がメントールであり、且つメントールの含有量が2~5重量%である、項1又は2に記載の外用医薬組成物。
項4. 非ステロイド性抗炎症薬、及びモノテルペンを含む外用医薬組成物の冷涼感を向上させる方法であって、
外用医薬組成物に、(A)非ステロイド性抗炎症薬、(B)モノテルペン、及び(C)プロピレングリコール10重量%超を配合する、冷涼感の向上方法。
本発明の外用医薬組成物は、(A)非ステロイド性抗炎症薬、(B)モノテルペン、及び(C)プロピレングリコールを含み、前記(C)成分の含有量が10重量%超であることを特徴とする。以下、本発明の外用医薬組成物について詳述する。
本発明の外用医薬組成物は、非ステロイド性抗炎症薬((A)成分と表記することもある)を含有する。非ステロイド性抗炎症薬とは、グルココルチコイド以外の抗炎症薬の総称である。
本発明の外用医薬組成物は、モノテルペン((B)成分と表記することもある)を含有する。モノテルペンとは、分子内にイソプレン単位が2個含まれる構造を有し、清涼化作用等を有する公知の成分である。
本発明の外用医薬組成物は、前記成分に加えて、プロピレングリコール((C)成分と表記することもある)を10重量%超の含有量で含有する。本発明の外用医薬組成物では、非ステロイド性抗炎症薬及びモノテルペンと共に、プロピレングリコールを10重量%超で含有させることによって、冷涼感を向上させることが可能になっている。プロピレングリコールとは、プロパン-1,2-ジオールとも称される2価低級アルコールである。
本発明の外用医薬組成物は、更に1価低級アルコールを含んでいてもよい。本発明において、1価低級アルコールとは炭素数1~5の1価アルコールを指す。
本発明の外用医薬組成物は、前述する成分の他に、必要に応じて、通常使用される他の添加剤が含まれていてもよい。このような添加剤としては、例えば、水、界面活性剤、植物油、動物油、鉱物油、脂肪酸アルキルエステル、脂肪酸、高級アルコール、pH調節剤、緩衝剤、可溶化剤、防腐剤、保存剤、酸化防止剤、安定化剤、香料、着色料等が挙げられる。本発明の外用医薬組成物において、これらの添加剤を含有させる場合、その含有量については、使用する添加剤の種類等に応じて適宜設定すればよい。
本発明の外用医薬組成物は、経皮適用できる剤型である限り、その製剤形態については、特に制限されず、液状又は半固形状(ゲル状、軟膏状、ペースト状)いずれであってもよいが、好ましくは液状が挙げられる。
本発明は、更に、非ステロイド性抗炎症薬、及びモノテルペンを含む外用医薬組成物の冷涼感を向上させる方法であって、外用医薬組成物に、(A)非ステロイド性抗炎症薬、(B)モノテルペン、及び(C)プロピレングリコール10重量%超を配合することを特徴とする、冷涼感の向上方法を提供する。
表1~3に記載の組成の外用医薬組成物(液剤)を調製した。得られた各外用医薬組成物が呈する冷涼感について評価した。具体的には、10名の被験者に各外用医薬組成物の約2gを内腕に塗布させ、塗布から30分後に塗布部における冷涼感について、20段階で評価した。冷涼感の評価は、「冷涼感が全くない」を1点、「参考例1-1、2-1又は3-1の外用医薬組成物を使用した場合に感じられる冷涼感」を15点、「極めて良好で高い冷涼感がある」を20点として、冷涼感の程度に応じて1~20点の20段階で評点化し、10名の被験者の評点の平均点を求めた。そして、比較例1-1、2-1又は3-1の外用医薬組成物を使用した場合の評点の平均点を100として、各外用医薬組成物を使用した場合の評点の平均点の割合を算出し、小数点第一位を四捨五入した値を冷涼感スコアとした。
表4に示す組成の外用医薬組成物を試験例1と同様の方法で調製し、試験例1と同様の方法で冷涼感を評価した。処方例1~12いずれの外用医薬組成物においても、処方例1~12においてプロピレングリコールを未配合に変更した外用医薬組成物と比較し、冷涼感の飛躍的な向上が認められた。
Claims (4)
- (A)非ステロイド性抗炎症薬、(B)モノテルペン、及び(C)プロピレングリコールを含み、
前記(C)成分の含有量が10重量%超である、外用医薬組成物。 - 前記(A)成分が、ロキソプロフェン、ジクロフェナク、フェルビナク、及びこれらの塩よりなる群から選択される少なくとも1種である、請求項1に記載の外用医薬組成物。
- 前記(B)成分がメントールであり、且つメントールの含有量が2~5重量%である、請求項1又は2に記載の外用医薬組成物。
- 非ステロイド性抗炎症薬、及びモノテルペンを含む外用医薬組成物の冷涼感を向上させる方法であって、
外用医薬組成物に、(A)非ステロイド性抗炎症薬、(B)モノテルペン、及び(C)プロピレングリコール10重量%超を配合する、冷涼感の向上方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180084998.6A CN116710140A (zh) | 2020-12-18 | 2021-11-11 | 外用医药组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-210320 | 2020-12-18 | ||
JP2020210320A JP2022096994A (ja) | 2020-12-18 | 2020-12-18 | 外用医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022130848A1 true WO2022130848A1 (ja) | 2022-06-23 |
Family
ID=82059037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/041550 WO2022130848A1 (ja) | 2020-12-18 | 2021-11-11 | 外用医薬組成物 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2022096994A (ja) |
CN (1) | CN116710140A (ja) |
TW (1) | TW202228669A (ja) |
WO (1) | WO2022130848A1 (ja) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05105628A (ja) * | 1991-10-14 | 1993-04-27 | Lion Corp | 外用消炎鎮痛剤 |
JPH06199701A (ja) * | 1992-12-29 | 1994-07-19 | Lion Corp | 外用消炎鎮痛剤 |
JPH0912452A (ja) * | 1995-06-27 | 1997-01-14 | Ss Pharmaceut Co Ltd | ジクロフェナクナトリウム含有乳化外用剤 |
JP2010083823A (ja) * | 2008-09-30 | 2010-04-15 | Kobayashi Pharmaceut Co Ltd | 外用関節痛治療剤 |
JP2015027971A (ja) * | 2013-07-31 | 2015-02-12 | 興和株式会社 | ロキソプロフェン含有外用塗布剤 |
JP2015193540A (ja) * | 2013-03-29 | 2015-11-05 | 興和株式会社 | ロキソプロフェン含有外用固形剤 |
JP2015214580A (ja) * | 2015-08-07 | 2015-12-03 | 小林製薬株式会社 | 皮膚外用剤 |
JP2017081902A (ja) * | 2015-10-30 | 2017-05-18 | 小林製薬株式会社 | 水中油型乳化組成物 |
JP2020011903A (ja) * | 2018-07-13 | 2020-01-23 | 大正製薬株式会社 | 外用組成物 |
-
2020
- 2020-12-18 JP JP2020210320A patent/JP2022096994A/ja active Pending
-
2021
- 2021-11-11 WO PCT/JP2021/041550 patent/WO2022130848A1/ja active Application Filing
- 2021-11-11 CN CN202180084998.6A patent/CN116710140A/zh active Pending
- 2021-11-16 TW TW110142464A patent/TW202228669A/zh unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05105628A (ja) * | 1991-10-14 | 1993-04-27 | Lion Corp | 外用消炎鎮痛剤 |
JPH06199701A (ja) * | 1992-12-29 | 1994-07-19 | Lion Corp | 外用消炎鎮痛剤 |
JPH0912452A (ja) * | 1995-06-27 | 1997-01-14 | Ss Pharmaceut Co Ltd | ジクロフェナクナトリウム含有乳化外用剤 |
JP2010083823A (ja) * | 2008-09-30 | 2010-04-15 | Kobayashi Pharmaceut Co Ltd | 外用関節痛治療剤 |
JP2015193540A (ja) * | 2013-03-29 | 2015-11-05 | 興和株式会社 | ロキソプロフェン含有外用固形剤 |
JP2015027971A (ja) * | 2013-07-31 | 2015-02-12 | 興和株式会社 | ロキソプロフェン含有外用塗布剤 |
JP2015214580A (ja) * | 2015-08-07 | 2015-12-03 | 小林製薬株式会社 | 皮膚外用剤 |
JP2017081902A (ja) * | 2015-10-30 | 2017-05-18 | 小林製薬株式会社 | 水中油型乳化組成物 |
JP2020011903A (ja) * | 2018-07-13 | 2020-01-23 | 大正製薬株式会社 | 外用組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN116710140A (zh) | 2023-09-05 |
JP2022096994A (ja) | 2022-06-30 |
TW202228669A (zh) | 2022-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6794420B2 (ja) | 外用医薬組成物 | |
JP6646390B2 (ja) | 外用組成物 | |
JP2018021002A (ja) | ロキソプロフェンを含有してなる医薬製剤 | |
JP6344947B2 (ja) | ロキソプロフェン含有外用固形剤 | |
WO2022130848A1 (ja) | 外用医薬組成物 | |
JPWO2013129545A1 (ja) | ロキソプロフェン含有外用固形剤 | |
JP6903411B2 (ja) | 外用組成物 | |
WO2022239715A1 (ja) | 外用組成物 | |
JP2018104368A (ja) | 外用組成物 | |
JP6929339B2 (ja) | 外用組成物 | |
JP6420101B2 (ja) | ロキソプロフェンを含有する外用塗布剤 | |
JP6114646B2 (ja) | ロキソプロフェン含有外用固形剤 | |
WO2022131083A1 (ja) | 外用医薬組成物 | |
JP7156825B2 (ja) | 外用医薬組成物 | |
WO2022131082A1 (ja) | 外用医薬組成物 | |
JP2019119684A (ja) | 外用組成物 | |
JP7412870B2 (ja) | 外用組成物 | |
JP7229678B2 (ja) | 外用医薬組成物 | |
JP2022096993A (ja) | 外用医薬組成物 | |
JP7301536B2 (ja) | 外用組成物 | |
JP7086596B2 (ja) | 外用組成物 | |
JP2022096992A (ja) | 外用医薬組成物 | |
JP2022176219A (ja) | 外用製剤 | |
JP2023092366A (ja) | 血行促進用組成物 | |
JP6420102B2 (ja) | ロキソプロフェン含有外用固形剤及び該外用固形剤の保存安定化剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21906212 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2301003583 Country of ref document: TH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180084998.6 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21906212 Country of ref document: EP Kind code of ref document: A1 |